Astrantus’s Integra LifeSciences IART Stock Holding History

Astrantus’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,100	Closed	-$208K	–	233
2021 Q4	$208K	Buy	+3,100	New	+$210K	0.16%	202

Other funds holding IART

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Astrantus's IART Position: Q1 2022 in Review

Astrantus sold out of Integra LifeSciences (IART) in Q1 2022, closing a stake of 3,100 shares — an estimated $208K sold.

Astrantus first reported a position in IART in Q4 2021 and held it in 1 quarter. The position peaked at $208K in Q4 2021. 278 funds tracked by Wall St. Rank hold IART as of Q1 2022.

Astrantus reported no remaining Integra LifeSciences position as of Q1 2022 after selling out during the quarter.
Astrantus sold 3,100 Integra LifeSciences shares in Q1 2022, an estimated $208K.
Astrantus first reported a position in Integra LifeSciences in Q4 2021 and held it in 1 quarter.
Astrantus's Integra LifeSciences position peaked at $208K in Q4 2021.
278 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.